Every 10-Q that Assembly Biosciences, Inc (ASMB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ASMB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ASMB filings page.
Assembly Biosciences, Inc. is a biotechnology company focused on therapeutics for serious viral and liver diseases, including recurrent genital herpes, hepatitis delta virus (HDV), cholestatic liver diseases, hepatitis B virus (HBV) and transplant‑related herpesviruses. For the quarter ended June 30, 2026, collaboration revenue from its related‑party agreement with Gilead Sciences was $13.4 million, up from $9.6 million a year earlier, while research and development and general and administrative expenses totaled $19.7 million, slightly below the prior‑year quarter. Net loss narrowed to $3.9 million for the quarter and $12.9 million for the first six months of 2026, compared with $10.2 million and $19.0 million in the respective 2025 periods, aided by $4.8 million of interest and other income in the first half.
Cash, cash equivalents and marketable securities were $320.4 million as of June 30, 2026, and management states this is sufficient to meet operating requirements for more than one year. During the first half, the company completed an underwritten offering of common stock and pre‑funded warrants providing net proceeds of about $108.1 million, increasing stockholders’ equity to $305.6 million. The Gilead collaboration continues to be central, with $21.6 million of first‑half collaboration revenue, an exercised option and exclusive license for the helicase‑primase inhibitor program, and ongoing eligibility for milestones and royalties across multiple programs.
Assembly Biosciences, Inc. reported a Q1 2026 net loss of $9.1M, slightly higher than the $8.8M loss a year earlier, as it continued investing in antiviral R&D. Collaboration revenue from Gilead was $8.2M, down from $9.4M, reflecting the timing of research services.
Total operating expenses were $19.6M, with research and development of $14.9M and general and administrative costs of $4.7M. Interest and other income rose to $2.3M due to a larger securities portfolio.
Cash, cash equivalents and marketable securities totaled $226.6M as of March 31, 2026, and management states this should fund operations into 2028. The company’s pipeline includes partnered genital herpes helicase‑primase inhibitors, HDV entry inhibitor ABI‑6250, capsid assembly modulator ABI‑4334 (now seeking partners) and NNPI candidate ABI‑7272.
Assembly Biosciences (ASMB) reported Q3 results and strengthened its balance sheet. Collaboration revenue was $10,789 thousand, up from $6,845 thousand a year ago. Operating expenses were $21,672 thousand, leading to a net loss of $9,196 thousand, or $0.72 per share. For the nine months, collaboration revenue reached $29,834 thousand and net loss was $28,212 thousand.
Liquidity improved materially. In August 2025, the company raised gross proceeds of $175.0 million through an underwritten offering and a concurrent private placement. As of September 30, 2025, cash, cash equivalents and marketable securities totaled $232.6 million. Management states these funds meet operating requirements beyond one year, resolving prior going concern conditions. Deferred revenue from a related party was $44,078 thousand, supporting ongoing program funding. Shares outstanding were 15,816,987 as of September 30, 2025; as of November 7, 2025, there were 15,817,140 shares outstanding.
Pipeline execution continued with multiple Phase 1 programs, and Gilead-related collaboration revenue and accounts receivable of $912 thousand reflected active cost sharing under the agreement.
What this filing says, in plain language
Assembly Biosciences is an early-stage biotech working on several antiviral drug programs. As of June 30, 2025, it held about $24.0 million in cash and $51.0 million in marketable securities (approximately $75.0 million total). Management says that amount is not sufficient to fund operations beyond one year, and the company has substantial doubt about its ability to continue as a going concern unless it secures more funding. The company recognized collaboration revenue from Gilead of $9.6 million this quarter ($19.0 million for the six months) and has deferred revenue from that collaboration of about $53.96 million, which supports near-term work. The company reported a net loss of $10.2 million this quarter ($19.0 million six months) and used $40.2 million in cash for operations in the first half of 2025. Clinically, Assembly reported positive early human data for two long-acting herpes drug candidates (5366 and 1179), topline antiviral results for its HBV candidate (4334), and ongoing Phase 1 work for its HDV entry inhibitor (6250). These results show scientific progress but the company has no approved products and needs additional financing to continue development.